Aandelen in “Farmaceutica”

Aandeel Datum Koers Evolutie
vlag Kala Pharmaceuticals Inc 20/05 6,630 USD
+1,22% 		+1,22%
vlag Kaleido Biosciences Inc 20/05 0,000 USD
0,00% 		0,00%
vlag KalVista Pharmaceuticals Inc 20/05 11,880 USD
-0,34% 		-0,34%
vlag Karuna Therapeutics Inc 15/03 329,830 USD
+0,03% 		+0,03%
vlag Keros Therapeutics Inc 20/05 52,370 USD
+0,17% 		+0,17%
vlag Kiniksa Pharmaceuticals Ltd 20/05 19,670 USD
-0,51% 		-0,51%
vlag Kronos Bio Inc 20/05 1,040 USD
+1,96% 		+1,96%
vlag Krystal Biotech Inc 20/05 164,450 USD
+0,21% 		+0,21%

Nieuws over “Farmaceutica”

07:30 · Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration · Persbericht

07:30 · Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration · Persbericht

20/05 · Sanofi: Information concerning the total number of voting rights and shares - April 2024 · Persbericht

20/05 · Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM · Persbericht

20/05 · Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine · Persbericht

17/05 · Novo Nordisk A/S - share repurchase programme · Persbericht

17/05 · Qilian International plans to adjust industrial investment · Persbericht

17/05 · AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® · Persbericht

17/05 · BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS · Persbericht

17/05 · AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc. · Persbericht

16/05 · CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

16/05 · Voting Rights and Shares Capital of the Company · Persbericht

16/05 · Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC · Persbericht

16/05 · Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress · Persbericht

16/05 · With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin · Persbericht

16/05 · Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash · Persbericht

16/05 · Bel-20 boekt licht herstel: grootste winst voor UCB · Trends (€)

Lees in deze blog een dagelijks overzicht van de belangrijkste korte financieel-economische nieuwsberichten uit binnen- en buitenland. The post Bel-20 boekt licht herstel: grootste winst voor UCB appeared first on Trends.

15/05 · NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 · Persbericht

15/05 · Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA · Persbericht

15/05 · Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) · Persbericht

15/05 · Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer · Persbericht

Mijn selecties